{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
carglumic acid
to a specific field?
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Corticorelin (Xerecept) is a synthetic analog of the naturally occurring human peptide corticotropin-releasing factor (CRF). Corticotropin-releasing factor is the predominant regulator of adrenocorticotropic-hormone (ACTH) formation and release by the pituitary. In addition to its primary location in the hypothalamic paraventricular nucleus, endogenous CRF has also been identified in cerebral cortical interneurons, the limbic system, brain stem and spinal cord. Several studies have indicated the ability of CRF to reduce the brain edema caused by brain tumors. Clinical trials with the Corticorelin (Xerecept) have indicated that this drug has a distinct advantage over classical corticosteroids in the treatment of brain edema. Fewer and/or milder side effects have been reported for corticorelin compared with dexamethasone, although at higher doses of corticorelin several side effects, including hypotension and transient flushing, have been reported.
Status:
Investigational
Source:
NCT01743807: Phase 1 Interventional Terminated Relapsed Acute Lymphoblastic Leukemia
(2012)
Source URL:
Class:
NUCLEIC ACID
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00002403: Phase 1 Interventional Completed HIV Infections
Source URL:
Class:
NUCLEIC ACID
Status:
Designated
Source:
EU-Orphan Drug:EU/3/19/2171
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2024)
Source:
NDA217424
(2024)
Source URL:
First approved in 2024
Source:
NDA217424
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2016)
Source:
NDA208114
(2016)
Source URL:
First approved in 2016
Source:
NDA208114
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2015)
Source:
NDA205739
(2015)
Source URL:
First approved in 2015
Source:
NDA205739
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2015)
Source:
NDA205739
(2015)
Source URL:
First approved in 2015
Source:
NDA205739
Source URL:
Class:
POLYMER
